Biogen Beats Q2 Estimates as Newer Drugs Drive Growth
Biogen reports $2.74B Q2 revenue, up 3% and beating estimates. Growth products surge 24%, rare-disease drugs rise 11%.
/ 12 items
#BIIB↓
Biogen’s Tau Drug Diranersen Shows Promise in Phase 2 but Misses Primary Endpoint
Despite missing the primary endpoint, the drug advances to Phase 3 in 2027 with a favorable safety profile.
FDA Approves First At-Home Starting Dose for Leqembi Alzheimer’s Treatment
RBC keeps Outperform at $242, Truist upgrades to Buy ($235 target).
Biogen Acquires RayThera for Up to $1 Billion to Expand Immunology Pipeline
The deal adds multiple early-stage small-molecule immunology assets to Biogen’s pipeline, with the lead candidate entering Phase 1 in Q3 2026.
Biogen’s Salanersen Wins FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy
Biogen’s new SMA drug Salanersen shows strong early results, helping kids move better. FDA fast-tracks it with Breakthrough status.
Parkinson’s Drug Targeting LRRK2 Fails Key Phase 2 Trial, Biogen and Denali Halt Development
Experimental Parkinson’s drug BIIB122 failed to slow disease in trials despite strong biological effects; development stopped.